The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection

Elizabeth A. Nelson; Julie Dyall; Thomas Hoenen; Alyson B. Barnes; Huanying Zhou; Janie Y. Liang; Julia Michelotti; William H. Dewey; Lisa Evans DeWald; Richard S. Bennett; Patrick J. Morris; Rajarshi Guha; Carleen Klumpp-Thomas; Crystal McKnight; Yu-Chi Chen; Xin Xu; Amy Wang; Emma Hughes; Scott Martin; Craig Thomas; Peter B. Jahrling; Lisa E. Hensley; Gene G. Olinger Jr.; Judith M. White

doi:10.1371/journal.pntd.0005540

Loading metrics

Open Access

Peer-reviewed

Research Article

The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection

Elizabeth A. Nelson,

Affiliation Department of Cell Biology, University of Virginia, Charlottesville, Virginia, United States of America
⨯
Julie Dyall,

Affiliation Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, United States of America
⨯
Thomas Hoenen,

Affiliations Laboratory of Virology, Division of Intramural Research, National Institutes of Health, Hamilton, Montana, United States of America, Institute of Molecular Virology and Cell Biology, Friedrich-Loeffler-Institut, Greifswald–Insel Riems, Germany
⨯
Alyson B. Barnes,

Affiliation Department of Cell Biology, University of Virginia, Charlottesville, Virginia, United States of America
⨯
Huanying Zhou,

Affiliation Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, United States of America
⨯
Janie Y. Liang,

Affiliation Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, United States of America
⨯
Julia Michelotti,

Affiliation Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, United States of America
⨯
William H. Dewey,

Affiliation Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, United States of America
⨯
Lisa Evans DeWald,

Affiliation Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, United States of America
⨯
Richard S. Bennett,

Affiliation Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, United States of America
⨯
Patrick J. Morris,

Affiliation Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, United States of America
⨯
Rajarshi Guha,

Affiliation Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, United States of America
⨯
Carleen Klumpp-Thomas,

Affiliation Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, United States of America
⨯
Crystal McKnight,

Affiliation Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, United States of America
⨯
Yu-Chi Chen,

Affiliation Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, United States of America
⨯
Xin Xu,

Affiliation Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, United States of America
⨯
Amy Wang,

Affiliation Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, United States of America
⨯
Emma Hughes,

Affiliation Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, United States of America
⨯
Scott Martin,

Affiliation Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, United States of America
⨯
Craig Thomas,

Affiliation Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, United States of America
⨯
Peter B. Jahrling,

Affiliations Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, United States of America, Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, United States of America
⨯
Lisa E. Hensley,

Affiliation Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, United States of America
⨯
Gene G. Olinger Jr.,

Affiliation Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, United States of America
⨯
[ ... ],
Judith M. White

* E-mail: jw7g@virginia.edu

Affiliation Department of Cell Biology, University of Virginia, Charlottesville, Virginia, United States of America

http://orcid.org/0000-0002-0532-996X

⨯
[ view all ]
[ view less ]

The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection

Elizabeth A. Nelson,
Julie Dyall,
Thomas Hoenen,
Alyson B. Barnes,
Huanying Zhou,
Janie Y. Liang,
Julia Michelotti,
William H. Dewey,
Lisa Evans DeWald,
Richard S. Bennett

Published: April 12, 2017
https://doi.org/10.1371/journal.pntd.0005540

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Ebola virus
Is the Subject Area "Ebola virus" applicable to this article?

Thanks for your feedback.
Endosomes
Is the Subject Area "Endosomes" applicable to this article?

Thanks for your feedback.
Phase II clinical investigation
Is the Subject Area "Phase II clinical investigation" applicable to this article?

Thanks for your feedback.
Macrophages
Is the Subject Area "Macrophages" applicable to this article?

Thanks for your feedback.
Transfection
Is the Subject Area "Transfection" applicable to this article?

Thanks for your feedback.
Cytoplasm
Is the Subject Area "Cytoplasm" applicable to this article?

Thanks for your feedback.
Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.
Cholesterol
Is the Subject Area "Cholesterol" applicable to this article?

Thanks for your feedback.